MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Brief Summary
This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm).

A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of \~50% of enrollees.
Brief Title
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
Detailed Description
Subjects with small vessel CAD (Coronary artery disease) presenting with lesions undergoing PCI (Percutaneous coronary intervention) will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or DCB (drug-coated balloon) on a 2:1 basis. Approximately 1605 subjects will be enrolled in the randomized study.

Treatment of a single lesion in a single major coronary artery or side branch will be enrolled per the inclusion and exclusion criteria. Target lesion must be located in a native coronary artery with a visually estimated diameter of\<2.75 mm to length (including tandem lesions) ≤34.0 mm by visual estimation, and diameter stenosis ≥50% to \<100% in symptomatic patients or ischemia by coronary physiology in patients without symptoms. The primary endpoint is TLF (target lesion failure) at 12 months after intervention.

All subjects providing informed consent will have their medical history reviewed and will undergo a physical examination, laboratory screen, and a standardized 12-lead ECG within 7 days of procedure. Women of childbearing potential will have a pregnancy test within one week prior to the procedure. SAQ-7 (Seattle Angina Questionnaire) will be collected at baseline, 30 days, 6 months, and 12 months and prior to any planned intervention.
Central Contacts
Central Contact Role
Contact
Central Contact Phone
+919725495366
Central Contact Email
farhana@conceptmedical.com
Central Contact Role
Contact
Central Contact Phone
+393292467132
Central Contact Email
dario@conceptmedical.com
Completion Date
Completion Date Type
Estimated
Conditions
Coronary Artery Disease
Native Coronary Artery Stenosis
Cardiovascular Diseases
Eligibility Criteria
Clinical Inclusion Criteria:

1. Adult patient with an indication for PCI due to stable angina, NSTEACS, post-infarction angina or silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, FFR ≤0.80, or non-hyperemic pressure ratio \[NHPR\] ≤0.89 must be present)
2. Subject is ≥18 and \<80 years old
3. Subject is willing to comply with all protocol-required follow-up evaluations and provides written informed consent

Angiographic Inclusion Criteria:
4. Target reference vessel diameter (visual estimation) ≤2.75 mm
5. Successful lesion preparation (residual stenosis \<30%), without flow-limiting complications (no or slow flow, dissection etc.)
6. Target lesion(s) in a native coronary artery
7. Up to two small vessel target lesions in two different vessels
8. Target lesion length (visual estimation): ≥6.0 and ≤34.0 mm and can be covered by a single 40 mm balloon
9. Target lesion diameter stenosis (visual estimation) \>30% and \<100% with Thrombolysis in Myocardial Infarction (TIMI) flow grade ≥2

Clinical Exclusion Criteria:

1. Planned (staged) intervention in the target vessel
2. ST-segment-elevation MI within 48 hours prior to index procedure
3. Subjects with acute cardiac decompensation or cardiogenic shock
4. Subject with a life expectancy of less than 24 months
5. Impaired renal function (glomerular filtration rate \[GFR\] \<30 mL/min)
6. Documented left ventricular ejection fraction (LVEF) ≤30%
7. Known allergies to acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, heparin, contrast medium, sirolimus or similar drugs (i.e., ABT-578 \[Zotarolimus\], biolimus, tacrolimus)
8. Relative or absolute contraindication to dual antiplatelet therapy (DAPT) for at least 1 month (e.g., planned surgeries that cannot be delayed)
9. Subject has an indication for chronic oral anticoagulation treatment and a contraindication for concomitant treatment with a P2Y12 inhibitor
10. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath
11. Hemoglobin \<9 g/dL
12. Platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3
13. White blood cell count \<3,000 cells/mm3
14. Active infection undergoing treatment
15. Clinically significant liver disease
16. Cerebrovascular accident (CVA) within 3 months or has any permanent neurological defect as a result of CVA
17. Subject is receiving oral or intravenous immunosuppressive therapy (e.g., inhaledsteroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
18. Subject is unlikely to comply with the follow up requirements, per investigator's assessment
19. Subject currently enrolled in other investigational device or drug trial in which primary endpoint has not been reached
20. Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study

Angiographic Exclusion Criteria:

All exclusion criteria apply to the target lesion(s) or target vessel(s)
21. Re-stenotic lesion(s), whether due to percutaneous old balloon angioplasty (POBA) or prior stenting
22. True bifurcation lesion (lesion involves both main and side branch\>2.5 mm) with planned treatment of both branches per investigator assessment
23. Angiographic evidence of thrombus in the target vessel
24. Myocardial bridging
25. Target lesion is heavily calcified
26. Diffuse distal disease to target lesion with impaired runoff, TIMI flow \<2
27. Non-target lesion in the target vessel requiring PCI

Note: Non-target vessel PCI is allowed at the time of index procedure if performed prior to study intervention and if successful and uncomplicated. For target lesions located in branches of the three main vessels (left anterior descending artery \[LAD\], left circumflex artery \[LCx\], right coronary artery \[RCA\]), the term target vessel refers to the branch and not the main vessel.
Inclusion Criteria
Inclusion Criteria:

1. Adult patient with an indication for PCI due to stable angina, NSTEACS, post-infarction angina or silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, FFR ≤0.80, or non-hyperemic pressure ratio \[NHPR\] ≤0.89 must be present)
2. Subject is ≥18 and \<80 years old
3. Subject is willing to comply with all protocol-required follow-up evaluations and provides written informed consent

Angiographic Inclusion Criteria:
4. Target reference vessel diameter (visual estimation) ≤2.75 mm
5. Successful lesion preparation (residual stenosis \<30%), without flow-limiting complications (no or slow flow, dissection etc.)
6. Target lesion(s) in a native coronary artery
7. Up to two small vessel target lesions in two different vessels
8. Target lesion length (visual estimation): ≥6.0 and ≤34.0 mm and can be covered by a single 40 mm balloon
9. Target lesion diameter stenosis (visual estimation) \>30% and \<100% with Thrombolysis in Myocardial Infarction (TIMI) flow grade ≥2

Clinical
Gender
All
Gender Based
false
Keywords
Drug coated balloon
Sirolimus coated balloon
De Novo
Magic Touch
SCB
Concept Medical
Small Vessel
MAGICAL SV
Healthy Volunteers
No
Last Update Submit Date
Maximum Age
80 Years
Minimum Age
18 Years
NCT Id
NCT06271590
Org Class
Industry
Org Full Name
Concept Medical Inc.
Org Study Id
CM-US-R03
Overall Status
Recruiting
Phases
Not Applicable
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
The MAGICAL SV Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Non Inferiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus-Coated Balloon in the Treatment of Small Vessels in Patients With Coronary Artery Disease.
Primary Outcomes
Outcome Description
the composite of cardiovascular mortality, target-vessel myocardial infarction (TV-MI) and ischemia driven target lesion revascularization
Outcome Measure
Target lesion failure (TLF)
Outcome Time Frame
within 12 months
Secondary Outcomes
Outcome Description
defined as residual diameter stenosis \<30% (DS), no flow-limiting dissection and with post-procedure The thrombolysis in myocardial infarction (TIMI) 3 flow, without the need for bailout stenting
Outcome Time Frame
at baseline, during the procedure
Outcome Measure
Procedural success
Outcome Description
defined as the composite of cardiovascular mortality, target-vessel myocardial infarction (TVMI) and ischemia driven target lesion revascularization
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Target lesion failure (TLF)
Outcome Description
Repeat revascularization of the target lesion due to recurrent ischemia
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Ischemia driven target vessel revascularization (ID-TVR)
Outcome Description
Repeat revascularization of the target vessel
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Target vessel revascularization (TVR)
Outcome Description
any repeat PCI
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Any revascularization
Outcome Description
defined as the composite of cardiovascular mortality,ischemia driven TVR and TVMI
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Target vessel failure (TVF)
Outcome Description
Myocardial Infarction demonstrated by new pathological Q waves on ECG
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Q-wave myocardial infarction (MI)
Outcome Description
Myocardial Infarction not demonstrated by new pathological Q waves on ECG
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Non Q-wave myocardial infarction (MI)
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Any myocardial infarction (MI)
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Target vessel myocardial infarction (TV MI)
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Spontaneous myocardial infarction (MI)
Outcome Time Frame
Evaluated at 48 hours
Outcome Measure
Procedural myocardial infarction (MI)
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Cardiovascular mortality
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
All-cause mortality
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Cardiovascular mortality or myocardial infarction (MI)
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
All-cause mortality or MI
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
All-cause mortality, myocardial infarction (MI) or target vessel revascularization (TVR)
Outcome Time Frame
Evaluated at 48 hours
Outcome Measure
Any probable or definite stent thrombosis
Outcome Description
Defined as per the Academic Research Consortium (ARC) criteria
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Probable stent thrombosis
Outcome Description
Defined as per the Academic Research Consortium (ARC) criteria
Outcome Time Frame
30 days and at 6, 12, 24, 36, 48, and 60 months
Outcome Measure
Definite stent thrombosis
Start Date
Start Date Type
Actual
Status Verified Date
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
80
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Mark Menegus
Investigator Email
mmenegus@montefiore.org
Investigator Department
Medicine
Investigator Division
Cardiology
Investigator Sponsor Organization
External
Study Department
Medicine
Study Division
Cardiology
Categories Mesh Debug
Blood Disorders --- CORONARY ARTERY DISEASE
Heart/Cardiovascular --- CORONARY ARTERY DISEASE
Blood Disorders --- CARDIOVASCULAR DISEASES
Blood & Bone Marrow Cancers --- CARDIOVASCULAR DISEASES
Heart/Cardiovascular --- CARDIOVASCULAR DISEASES
Heart/Cardiovascular --- MYOCARDIAL ISCHEMIA
Brain, Spinal Cord & Nervous System --- HEART DISEASES
Heart/Cardiovascular --- HEART DISEASES
Heart/Cardiovascular --- ARTERIOSCLEROSIS
Heart/Cardiovascular --- ARTERIAL OCCLUSIVE DISEASES
Blood & Bone Marrow Cancers --- VASCULAR DISEASES
Heart/Cardiovascular --- VASCULAR DISEASES
MeSH Terms
CORONARY ARTERY DISEASE
CARDIOVASCULAR DISEASES
CORONARY DISEASE
MYOCARDIAL ISCHEMIA
HEART DISEASES
ARTERIOSCLEROSIS
ARTERIAL OCCLUSIVE DISEASES
VASCULAR DISEASES
DRUG-ELUTING STENTS
STENTS
PROSTHESES AND IMPLANTS
EQUIPMENT AND SUPPLIES